Literature DB >> 15555704

Electroconvulsive therapy in depressive illness that has not responded to drug treatment.

Syed S Husain1, Ian Mark Kevan, Rebecca Linnell, Allan I F Scott.   

Abstract

BACKGROUND: Antidepressant medication resistance is the commonest indication for electroconvulsive therapy (ECT) in Scotland. Evidence from the USA suggests that clinical response is reduced for medication resistant patients. The aim of the present study was to establish if the American results were generalisable to routine clinical practice in Edinburgh.
METHOD: Fifty eligible depressed patients consecutively referred for a new course of bilateral ECT at the Royal Edinburgh Hospital were prospectively assessed as part of the National Audit of ECT in Scotland. The patients were categorised into those who had received adequate drug treatment pre-ECT (and could therefore be classed as medication resistant) and those who had not, using five operational definitions. The clinical response of the ECT was then compared between groups, using the Montgomery-Asberg Rating Scale for Depression (MADRS) and Clinical Global Impression Scale (CGI).
RESULTS: Patients defined as medication resistant had an identical response to patients who were not defined as medication resistant (in both groups 60% met the predetermined criterion for clinical response), and this was consistent across the five operational definitions.
CONCLUSIONS: The hypothesis that medication resistance is associated with a reduced probability of clinical response to ECT was not supported. LIMITATIONS: Some patients who were inadequately drug treated might have proven eventually to be medication resistant, which would have obscured a potential difference in clinical response. It is not known how generalisable the results are to clinical practice in the rest of the UK.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15555704     DOI: 10.1016/j.jad.2004.05.006

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  10 in total

1.  Alterations in patients with major depressive disorder before and after electroconvulsive therapy measured by fractional amplitude of low-frequency fluctuations (fALFF).

Authors:  Haitang Qiu; Xinke Li; Qinghua Luo; Yongming Li; Xichuan Zhou; Hailin Cao; Yuanhong Zhong; Mingui Sun
Journal:  J Affect Disord       Date:  2018-10-09       Impact factor: 4.839

2.  Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder.

Authors:  Wallace C Duncan; Simone Sarasso; Fabio Ferrarelli; Jessica Selter; Brady A Riedner; Nadia S Hejazi; Peixiong Yuan; Nancy Brutsche; Husseini K Manji; Giulio Tononi; Carlos A Zarate
Journal:  Int J Neuropsychopharmacol       Date:  2012-06-07       Impact factor: 5.176

3.  Global decrease of serotonin-1A receptor binding after electroconvulsive therapy in major depression measured by PET.

Authors:  R Lanzenberger; P Baldinger; A Hahn; J Ungersboeck; M Mitterhauser; D Winkler; Z Micskei; P Stein; G Karanikas; W Wadsak; S Kasper; R Frey
Journal:  Mol Psychiatry       Date:  2012-07-03       Impact factor: 15.992

4.  Modulation of interhemispheric functional coordination in electroconvulsive therapy for depression.

Authors:  Q Wei; Y Tian; Y Yu; F Zhang; X Hu; Y Dong; Y Chen; P Hu; X Hu; K Wang
Journal:  Transl Psychiatry       Date:  2014-09-30       Impact factor: 6.222

5.  The Changes of Functional Connectivity Strength in Electroconvulsive Therapy for Depression: A Longitudinal Study.

Authors:  Qiang Wei; Tongjian Bai; Yang Chen; Gongjun Ji; Xiaopeng Hu; Wen Xie; Zulun Xiong; Daomin Zhu; Lin Wei; Panpan Hu; Yongqiang Yu; Kai Wang; Yanghua Tian
Journal:  Front Neurosci       Date:  2018-09-25       Impact factor: 4.677

Review 6.  Ketamine and depression: a narrative review.

Authors:  Alexandrine Corriger; Gisèle Pickering
Journal:  Drug Des Devel Ther       Date:  2019-08-27       Impact factor: 4.162

7.  Repetitive enhancement of serum BDNF subsequent to continuation ECT.

Authors:  T Vanicek; G S Kranz; B Vyssoki; A Komorowski; G Fugger; A Höflich; Z Micskei; S Milovic; R Lanzenberger; A Eckert; S Kasper; R Frey
Journal:  Acta Psychiatr Scand       Date:  2019-09-11       Impact factor: 6.392

8.  Electroconvulsive therapy modulates functional interactions between submodules of the emotion regulation network in major depressive disorder.

Authors:  Jinping Xu; Qiang Wei; Tongjian Bai; Lijie Wang; Xuemei Li; Zhengyu He; Jianhuang Wu; Qingmao Hu; Xun Yang; Chao Wang; Yanghua Tian; Jiaojian Wang; Kai Wang
Journal:  Transl Psychiatry       Date:  2020-08-05       Impact factor: 6.222

9.  Follow-up Study on Electroconvulsive Therapy in Treatment-resistant Depressed Patients after Remission: A Chart Review.

Authors:  Yuki Tokutsu; Wakako Umene-Nakano; Takahiro Shinkai; Reiji Yoshimura; Tatsuya Okamoto; Asuka Katsuki; Hikaru Hori; Atsuko Ikenouchi-Sugita; Kenji Hayashi; Kiyokazu Atake; Jun Nakamura
Journal:  Clin Psychopharmacol Neurosci       Date:  2013-04-24       Impact factor: 2.582

10.  Modulation of functional network properties in major depressive disorder following electroconvulsive therapy (ECT): a resting-state EEG analysis.

Authors:  Aron T Hill; Itay Hadas; Reza Zomorrodi; Daphne Voineskos; Faranak Farzan; Paul B Fitzgerald; Daniel M Blumberger; Zafiris J Daskalakis
Journal:  Sci Rep       Date:  2020-10-13       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.